Insulin resistance and risk of venous thromboembolism: results of a population‐based cohort study

Schouwenburg, Inge M. van; Mahmoodi, Bakhtawar K.; Veeger, Nic J. G. M.; Bakker, Stephan J. L.; Kluin-Nelemans, Hanneke C.; Meijer, Karina; Gansevoort, Ron T.

doi:10.1111/j.1538-7836.2012.04707.x

Cited by 28 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of insulin resistance is increased in obese individuals [42], and improves with weight loss [43][44][45]. Schouwenburg et al [46] showed that insulin resistance was not associated with the risk of VTE after adjustment for BMI in a population-based cohort. In contrast, a recent report from the Iowa Women's Health Study [18] showed an association between diabetes and VTE in women, even after adjustment for BMI.…”

Section: Discussionmentioning

confidence: 99%

Hyperglycemia, assessed according to HbA1c, and future risk of venous thromboembolism: the Tromsø study

Lerstad

Brodin

Enga

et al. 2014

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

NorwayTo cite this article: Lerstad G, Brodin EE, Enga KF, Jorde R, Schirmer H, Njølstad I, Svartberg J, Braekkan SK, Hansen J-B. Hyperglycemia, assessed according to HbA 1c , and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost 2014; 12: 313-9.Summary. Background: HbA 1c , a marker of average plasma glucose level during the previous 8-12 weeks, is associated with the future risk of cardiovascular disease and all-cause mortality. Objectives: To examine the association between hyperglycemia, assessed according to HbA 1c , and the future risk of venous thromboembolism (VTE) in a population-based cohort. Methods: HbA 1c was measured in 16 156 unique subjects (25-87 years) who participated in one or more surveys of the Tromsø study (Tromsø 4, 1994(Tromsø 4, -1995 Tromsø 5, 2001 Tromsø 5, -2002 and Tromsø 6, 2007-2008). All subjects were followed, and incident VTE events were recorded up to 31 December 2010. Results: There were 333 validated first VTE events, of which 137 were unprovoked, during a median followup of 7.1 years. HbA 1c was not associated with the future risk of VTE in analyses treating HbA 1c as a continuous variable, or in categorized analyses. The risk of VTE increased by 5% per one standard deviation (0.7%) increase in HbA 1c (multivariable-adjusted hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.97-1.14), and subjects with HbA 1c ≥ 6.5% had a 27% higher risk than those with HbA 1c < 5.7% (multivariable-adjusted HR 1.27; 95% CI 0.72-2.26). There was no significant linear trend for an increased risk of VTE across categories of HbA 1c (P = 0.27). Conclusions: Serum levels of HbA1c were not associated with the future risk of VTE in multivariable analysis. Our findings suggest that hyperglycemia does not play an important role in the pathogenesis of VTE.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperglycemia, assessed according to HbA1c, and future risk of venous thromboembolism: the Tromsø study

Lerstad

Brodin

Enga

et al. 2014

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…It is, thus, legitimate to ask whether IR itself is a risk factor for VTE. Unfortunately, little information is available and only one large prospective population-based cohort study specifically addressed this issue, showing that individuals with higher IR scores had an increased risk of unprovoked VTE, which was independent of several related risk factors, but not BMI (Van Schouwenburg et al 2012).…”

Section: Insulin Resistance As a Predictor Of Venous Thromboembolism mentioning

confidence: 99%

Insulin resistance as a predictor of venous thromboembolism in breast cancer

Ferroni

Roselli

Cavaliere

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Extract: It is generally accepted that women with breast cancer (BC) have an increased risk of venous thromboembolism (VTE) compared with women of matching age, but no cancer. Metastatic disease, chemotherapy and tamoxifen treatment are all risk factors for increased VTE risk. Particularly, a 6% annual VTE incidence while undergoing chemotherapy, and up to one month after, has been recently reported in a cohort study, showing that VTE risk was markedly higher in the 3 months after initiation of tamoxifen, but not aromatase inhibitors ..

show abstract

“…This process ultimately leads to a prothrombotic tendency by enhancing coagulation while inhibiting fibrinolysis [78,79], which in some cases can contribute to the pathogenesis of VTE associated with abdominal obesity [32]. Indeed, insulin resistance has been reported to increase the risk of VTE in a BMI-dependent manner [80].…”

Section: In Relation To Inflammation and Insulin Resistancementioning

confidence: 99%

The effects of obesity on venous thromboembolism: A review

Yang¹,

Staercke²,

Hooper³

2012

OJPM

132

View full text Add to dashboard Cite

Obesity has emerged as a global health issue that is associated with wide spectrum of disorders, including coronary artery disease, diabetes mellitus, hypertension, stroke, and venous thromboembolism (VTE). VTE is one of the most common vascular disorders in the United States and Europe and is associated with significant mortality. Although the association between obesity and VTE appears to be moderate, obesity can interact with other environmental or genetic factors and pose a significantly greater risk of VTE among individuals who are obese and who are exposed simultaneously to several other risk factors for VTE. Therefore, identification of potential interactions between obesity and certain VTE risk factors might offer some critical points for VTE interventions and thus minimize VTE morbidity and mortality among patients who are obese. However, current obesity measurements have limitations and can introduce contradictory results in the outcome of obesity. To overcome these limitations, this review proposes several future directions and suggests some avenues for prevention of VTE associated with obesity as well.

show abstract

Insulin resistance and risk of venous thromboembolism: results of a population‐based cohort study

Cited by 28 publications

References 37 publications

Hyperglycemia, assessed according to HbA1c, and future risk of venous thromboembolism: the Tromsø study

Hyperglycemia, assessed according to HbA1c, and future risk of venous thromboembolism: the Tromsø study

Insulin resistance as a predictor of venous thromboembolism in breast cancer

The effects of obesity on venous thromboembolism: A review

Contact Info

Product

Resources

About